Corbus Pharmaceuticals, Inc.

117 articles about Corbus Pharmaceuticals, Inc.

• Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

  11/7/2023

  Corbus Pharmaceuticals Holdings, Inc. today provided a corporate update and reported financial results for the third quarter of 2023.

• Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

  11/2/2023

  Corbus Pharmaceuticals Holdings, Inc. announced that results from two pre-clinical studies on its CRB-601 anti-aVb8 integrin monoclonal antibody were presented as posters at the 38th Annual Meeting of the Society for Immunotherapy of Cancer, being held in San Diego, CA November 1-5, 2023.

• Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023

  10/3/2023

  Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the development of a next generation Nectin-4 antibody drug conjugate, focusing on opportunities and challenges for CRB-701, on Tuesday, October 10, 2023 at 10:30am ET.

• Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  9/19/2023

  Corbus Pharmaceuticals Holdings, Inc. today announced the pre-clinical data on its CRB-701 Nectin-4 anti-drug-conjugate (ADC) will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

• Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

  8/8/2023

  Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today provided a corporate update and reported financial results for the second quarter of 2023.

• Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

  7/31/2023

  Corbus Pharmaceuticals Holdings, Inc. today announced that Yuval Cohen , Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the BTIG Virtual Biotechnology Conference, to be held August 7-8, 2023.

• Corbus Pharmaceuticals Set to Join Russell Microcap® Index

  6/26/2023

  Corbus Pharmaceuticals Holdings, Inc. today announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens today.

• Corbus Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference

  5/31/2023

  Corbus Pharmaceuticals Holdings, Inc. today announced that Yuval Cohen , Ph.D., Chief Executive Officer of Corbus, will participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference, to be held in New York, NY June 7-9, 2023.

• Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

  5/9/2023

  Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today provided a corporate update and reported financial results for the first quarter of 2023.

• Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on CRB-601 avβ8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy Meeting

  5/1/2023

  Corbus Pharmaceuticals Holdings, Inc. today announced that an abstract highlighting pre-clinical data for CRB-601, its avβ8 blocking antibody, has been accepted for oral presentation in the main program of the New York Academy of Sciences' 2023 Frontiers in Cancer Immunotherapy meeting, taking place in New York, NY May 2-4, 2023.

• Corbus Pharmaceuticals Hosting Virtual 'Meet the Expert' Series: Blocking TGFβ with CRB-601--a New Play for an Old Target

  4/18/2023

  Corbus Pharmaceuticals Holdings, Inc., a precision oncology company, announced that the Company will host the first in the series of virtual 'Meet the Expert' events titled Blocking TGFβ with CRB-601—a New Play for an Old Target, on April 25th at 11:00 AM ET.

• Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting

  4/17/2023

  Corbus Pharmaceuticals Holdings, Inc. today announced details of new pre-clinical data on CRB-601, its avβ8 blocking antibody, presented as a poster at the 2023 American Association for Cancer Research (AACR) annual meeting, held April 14-19, 2023 in Orlando, FL.

• Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update

  3/7/2023

  Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today provided a corporate update and reported financial results for the fourth quarter and year-end of 2022.

• Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA

  3/6/2023

  Corbus Pharmaceuticals Holdings, Inc., a precision oncology company, announced the appointment of Yong Ben, M.D., MBA, to the Company's Board of Directors.

• Corbus Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

  3/2/2023

  Corbus Pharmaceuticals Holdings, Inc. today announced that Yuval Cohen , Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Oppenheimer 33rd Annual Healthcare Conference.

• Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

  11/10/2022

  Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an oncology company, is presenting new preclinical data for CRB-601 today in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston.

• Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/8/2022

  Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an oncology company, today provided a corporate update and reported financial results for the third quarter of 2022.

• 

  Surface, Immutep and Corbus Move Beyond Anti-PD-1/PD-LI with New Targets

  10/19/2022

  PD-L1 expression is not the static, “yes/no” predictor of tumor response for which researchers hoped. Surface Oncology, Immutep and Corbus are each taking a different approach to immuno-oncology.

• Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors

  9/26/2022

  Corbus Pharmaceuticals Holdings, Inc. today announced the appointment of Anne Altmeyer, PhD, MBA, MPH to its board of directors.  

• Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/9/2022

  Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided a corporate update and reported financial results for the first quarter of 2022.